Marker Therapeutics, Inc. (MRKR) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Marker Therapeutics, Inc. (MRKR), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Marker Therapeutics, Inc., analysts forecast revenue rising from $3.11M in 2025 to $325.47M in 2030; the average estimate for 2030 earnings per share is $5.23; with published estimates ranging from −$0.30 to $9.77; 3 analysts contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Marker Therapeutics, Inc. (MRKR) forecast — frequently asked questions
What are analysts forecasting for Marker Therapeutics, Inc.'s earnings?
The average analyst estimate for Marker Therapeutics, Inc. (MRKR) earnings per share in 2030 is 5.23, with individual estimates between -0.30 and 9.77.
How much revenue is Marker Therapeutics, Inc. expected to make?
Analysts forecast Marker Therapeutics, Inc. (MRKR) revenue of $325.47M in 2030, based on 2 published estimates.
How many analysts cover MRKR?
3 analysts contribute estimates for Marker Therapeutics, Inc. (MRKR). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.